): The Research Training Grant in Oncology to be utilized by the Section of Hematology/Oncology at the University of Chicago is intended to train the future physician-scientists in Oncology in this country. It is intended to continue a successful training record where over 70% of trainees have obtained first-time full- time academic positions. It is designed to train internal medicine physicians who have completed a full-time clinical year in oncology in the nature of either basic or clinical research in oncology. It is intended that the basic research training will take at least two additional years and possible three. Trainees will be advised and guided by an experienced Program Director and Executive Committee who have participated in their selection of and are committed to their academic development. Trainees will select a sponsor and work within the area of the sponsor. Choices consist of approximately 16 areas ranging from chromosome translocations in hematologic malignancies and drug development through cancer outcomes and research ethics. The trainee will learn how to vertically integrate the knowledge and experience gained so that he or she will be able to be successful as a physician-scientist in the future regardless of whether the major emphasis is in basic or clinical research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA009566-13
Application #
2894407
Study Section
Subcommittee G - Education (NCI)
Program Officer
Gorelic, Lester S
Project Start
1987-09-05
Project End
2002-06-30
Budget Start
1999-07-01
Budget End
2000-06-30
Support Year
13
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
225410919
City
Chicago
State
IL
Country
United States
Zip Code
60637
West, Allison H; Blazer, Kathleen R; Stoll, Jessica et al. (2018) Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk. Fam Cancer 17:495-505
Trujillo, Jonathan A; Sweis, Randy F; Bao, Riyue et al. (2018) T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol Res 6:990-1000
Veneris, Jennifer Taylor; Darcy, Kathleen M; Mhawech-Fauceglia, Paulette et al. (2017) High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecol Oncol 146:153-160
Sweis, Randy F; Medved, Milica; Towey, Shannon et al. (2017) Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer 15:207-212
Curran, Emily; Chen, Xiufen; Corrales, Leticia et al. (2016) STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia. Cell Rep 15:2357-66
Sweis, Randy F; Ratain, Mark J (2016) Reply to T.A. Yap et al. J Clin Oncol 34:2432-3
Pettit, Kristen; Stock, Wendy; Walter, Roland B (2016) Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia. Leuk Lymphoma 57:1527-33
Brewer, Jamie R; Morrison, Gladys; Dolan, M Eileen et al. (2016) Chemotherapy-induced peripheral neuropathy: Current status and progress. Gynecol Oncol 140:176-83
Sweis, Randy F; Drazer, Michael W; Ratain, Mark J (2016) Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials. J Clin Oncol 34:369-74
Bestvina, Christine M; Fleming, Gini F (2016) Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings. Oncologist 21:1250-1259

Showing the most recent 10 out of 59 publications